Millennium Management’s Viridian Therapeutics VRDN Stock Holding History

Millennium Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-105,500	Closed	-$2.51M	–	6616
2023 Q2	$2.51M	Buy	+105,500	New	+$2.71M	﹤0.01%	3278
2023 Q1	–	Sell	-90,400	Closed	-$2.64M	–	6902
2022 Q4	$2.64M	Buy	+90,400	New	+$2.08M	﹤0.01%	3329

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management's VRDN Position: Q2 2026 in Review

Millennium Management sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 140,595 shares — an estimated $2.75M sold.

Millennium Management first reported a position in VRDN in Q1 2017 and held it in 30 quarters. The position peaked at $31.8M in Q2 2023. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Millennium Management reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Millennium Management sold 140,595 Viridian Therapeutics shares in Q2 2026, an estimated $2.75M.
Millennium Management first reported a position in Viridian Therapeutics in Q1 2017 and held it in 30 quarters.
Millennium Management's Viridian Therapeutics position peaked at $31.8M in Q2 2023.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.